<DOC>
	<DOC>NCT00426530</DOC>
	<brief_summary>This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.</brief_summary>
	<brief_title>Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criteria: Female or male patients ≥18 years with WHO performance status ≤ 1 HER2 overexpressing metastatic breast cancer cells confirmed by histology Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy Patients neurologically stable with adequate bone marrow, liver and renal function Exclusion criteria: Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study treatment start Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these ≤ 4 weeks prior to study treatment start or patients who have received lapatinib ≤ 2 weeks prior to study treatment start Patients who have previously received vinorelbine or mTOR inhibitors Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HER2-overexpressing metastatic breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Cancer of the breast</keyword>
	<keyword>Human mammary carcinoma</keyword>
	<keyword>HER-2</keyword>
	<keyword>metastatic</keyword>
	<keyword>everolimus</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>vinorelbine</keyword>
</DOC>